• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.

作者信息

Harrington Patrick, Kurshan Ashwini, Delord Marc, Lechmere Thomas, Sheikh Amna, Saunders Jamie, Saha Chandan, Dillon Richard, Woodley Claire, Asirvatham Susan, Curto-Garcia Natalia, Sullivan Jennifer O', Kordasti Shahram, Radia Deepti, McLornan Donal, Malim Michael H, Harrison Claire, Doores Katie J, de Lavallade Hugues

机构信息

Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

School of Cancer and Pharmaceutical Science, King's College London, London, United Kingdom.

出版信息

Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375.

DOI:10.1182/bloodadvances.2022008375
PMID:36083126
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9472701/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed7/10234122/53e771b5875a/BLOODA_ADV-2022-008375-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed7/10234122/b69530d45923/BLOODA_ADV-2022-008375-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed7/10234122/53e771b5875a/BLOODA_ADV-2022-008375-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed7/10234122/b69530d45923/BLOODA_ADV-2022-008375-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed7/10234122/53e771b5875a/BLOODA_ADV-2022-008375-gr2.jpg

相似文献

1
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗可增强慢性髓系疾病患者对奥密克戎变异株的中和作用。
Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375.
2
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
3
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
4
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.心脏移植受者接种第三剂 BNT162B2 疫苗后 6 个月内细胞和体液反应的动力学——对奥密克戎变异株的影响。
J Heart Lung Transplant. 2022 Oct;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014. Epub 2022 May 24.
5
Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.肾移植受者接种第三剂 mRNA SARS-CoV-2 疫苗后对 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株的中和抗体反应。
Am J Transplant. 2022 Jul;22(7):1873-1883. doi: 10.1111/ajt.17054. Epub 2022 Apr 18.
6
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.原型株和奥密克戎 RBD mRNA 疫苗对奥密克戎变异株中和效力。
Front Immunol. 2022 Jun 30;13:908478. doi: 10.3389/fimmu.2022.908478. eCollection 2022.
7
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
8
SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.接受抑制性抗逆转录病毒疗法的 HIV 感染者接种四剂 COVID-19 疫苗后对 SARS-CoV-2 活病毒的中和作用。
AIDS. 2023 Apr 1;37(5):F11-F18. doi: 10.1097/QAD.0000000000003519. Epub 2023 Feb 14.
9
Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.重复接种 COVID-19 mRNA 疫苗后对 SARS-CoV-2 奥密克戎亚变种的交叉中和作用。
J Med Virol. 2023 Jan;95(1):e28268. doi: 10.1002/jmv.28268. Epub 2022 Nov 10.
10
Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.接种 COVID-19 mRNA 疫苗加强针对日本养老院队列中奥密克戎亚变种 BA.1 和 BA.5 的中和作用。
Vaccine. 2023 Mar 24;41(13):2234-2242. doi: 10.1016/j.vaccine.2023.02.068. Epub 2023 Feb 27.

本文引用的文献

1
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.接受鲁索替尼治疗的慢性骨髓增殖性肿瘤患者对SARS-CoV-2疫苗接种的体液和T细胞反应受损。
Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.
2
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.新冠疫苗接种者中不同的 SARS-CoV-2 奥密克戎反应性 T 和 B 细胞应答。
Sci Immunol. 2022 Mar 25;7(69):eabo2202. doi: 10.1126/sciimmunol.abo2202.
3
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的重复疫苗接种在异基因干细胞移植受者中引发强大的多功能T细胞反应。
Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12.
4
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.mRNA SARS-CoV-2 疫苗接种后，即使在伴有淋巴恶性肿瘤的患者中未发生血清转换，也常常能检测到 T 细胞免疫应答。
Br J Haematol. 2022 Feb;196(3):548-558. doi: 10.1111/bjh.17877. Epub 2021 Oct 14.
5
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer.接种SARS-CoV-2 mRNA疫苗的癌症患者的体液免疫和细胞免疫反应。
Cancer Cell. 2021 Sep 13;39(9):1171-1172. doi: 10.1016/j.ccell.2021.08.001. Epub 2021 Aug 17.
6
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.一剂 BNT162b2 mRNA 疫苗可诱导慢性髓性白血病患者产生针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体和多功能 T 细胞反应。
Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.
9
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
10
Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm.预测无症状男性患前列腺癌的风险：一项开发和验证新算法的队列研究
Br J Gen Pract. 2021 Apr 29;71(706):e364-e371. doi: 10.3399/bjgp20X714137. Print 2021 May.